Vascular endothelial growth inhibitor in human cancer

International Journal of Molecular Medicine

Volumn 24, Issue 1, 2009, Pages 3-8

  Zhang, Ning ^a,b   Sanders, Andrew J ^b   Ye, Lin ^b   Jiang, Wen G ^b  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

Angiogenesis; Carcinoma; Vascular endothelial growth inhibitor

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; DEATH RECEPTOR 3; DECOY RECEPTOR 3; RECOMBINANT VASCULAR ENDOTHELIAL GROWTH INHIBITOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULAR ENDOTHELIAL GROWTH INHIBITOR; VASCULAR ENDOTHELIAL GROWTH INHIBITOR 174; VASCULAR ENDOTHELIAL GROWTH INHIBITOR 192; VASCULAR ENDOTHELIAL GROWTH INHIBITOR 251; VASCULAR ENDOTHELIAL GROWTH INHIBITOR [24-174]; VASCULAR ENDOTHELIAL GROWTH INHIBITOR [72-251];

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; AUTOCRINE EFFECT; BIOLOGICAL ACTIVITY; BREAST CANCER; CANCER INHIBITION; CANCER SURVIVAL; CARCINOMA; CELL CYCLE REGULATION; CELL MATURATION; CELL PROLIFERATION; CELL STIMULATION; CELLULAR DISTRIBUTION; COLON CANCER; DENDRITIC CELL; DRUG BINDING SITE; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG TARGETING; ENDOTHELIUM CELL; GENE EXPRESSION REGULATION; HUMAN; IMMUNE RESPONSE; LUNG CANCER; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SOLID TUMOR; SURVIVAL TIME; T LYMPHOCYTE ACTIVATION; TISSUE DISTRIBUTION;

ANGIOGENESIS INHIBITORS; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN ISOFORMS; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 15;

EID: 67649546995     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm_00000198     Document Type: Review

References (58)

1. Tan KB, Harrop J, Reddy M, et al: Characterization of a novel TNF-like ligand and recently described TNF ligand and TNF receptor superfamily genes and their constitutive and inducible expression in hematopoietic and non-hematopoietic cells. Gene 204: 35-46, 1997.
2. Zhai Y, Ni J, Jiang GW, et al: VEGI, a novel cytokine of the tumor necrosis factor family, is an angiogenesis inhibitor that suppresses the growth of colon carcinomas in vivo. FASEB J 13: 181-189, 1999.
3. Bamias G, Martin C 3rd, Marini M, et al: Expression, localization, and functional activity of TL1A, a novel Th1-polarizing cytokine in inflammatory bowel disease. J Immunol 171: 4868-4874, 2003.
4. Prehn JL, Mehdizadeh S, Landers CJ, et al: Potential role for TL1A, the new TNF-family member and potent costimulator of IFN-gamma, in mucosal inflammation. Clin Immunol 112: 66-77, 2004.
5. Al-Lamki RS, Wang J, Tolkovsky AM, et al: TL1A both promotes and protects from renal inflammation and injury. J Am Soc Nephrol 19: 953-960, 2008.
6. Bamias G, Siakavellas SI, Stamatelopoulos KS, Chryssochoou E, Papamichael C and Sfikakis PP: Circulating levels of TNF-like cytokine 1A (TL1A) and its decoy receptor 3 (DcR3) in rheumatoid arthritis. Clin Immunol 129: 249-255, 2008.
7. Jin T, Guo F, Kim S, Howard A and Zhang YZ: X-ray crystal structure of TNF ligand family member TL1A at 2.1A. Biochem Biophys Res Commun 364: 1-6, 2007.
8. Zhai Y, Yu J, Iruela-Arispe L, et al: Inhibition of angiogenesis and breast cancer xenograft tumor growth by VEGI, a novel cytokine of the TNF superfamily. Int J Cancer 82: 131-136, 1999.
9. Parr C, Gan CH, Watkins G and Jiang WG: Reduced vascular endothelial growth inhibitor (VEGI) expression is associated with poor prognosis in breast cancer patients. Angiogenesis 9: 73-81, 2006.
10. Hou W, Medynski D, Wu S, Lin X and Li LY: VEGI-192, a new isoform of TNFSF15, specifically eliminates tumor vascular endothelial cells and suppresses tumor growth. Clin Cancer Res 11: 5595-5602, 2005.
11. Haridas V, Shrivastava A, Su J, et al: VEGI, a new member of the TNF family activates nuclear factor-kappa B and c-Jun N-terminal kinase and modulates cell growth. Oncogene 18: 6496-6504, 1999.
12. Yu J, Tian S, Metheny-Barlow L, et al: Modulation of endothelial cell growth arrest and apoptosis by vascular endothelial growth inhibitor. Circ Res 89: 1161-1167, 2001.
13. Granger GA, Shacks SJ, Williams TW and Kolb WP: Lymphocyte in vitro cytotoxicity: specific release of lymphotoxin-like materials from tuberculin-sensitive lymphoid cells. Nature 221: 1155-1157, 1969.
14. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N and Williamson B: An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 72: 3666-3670, 1975.
15. Gray PW, Aggarwal BB, Benton CV, et al: Cloning and expression of cDNA for human lymphotoxin, a lymphokine with tumour necrosis activity. Nature 312: 721-724, 1984.
16. Pennica D, Nedwin GE, Hayflick JS, et al: Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin. Nature 312: 724-729, 1984.
17. Younes A and Kadin ME: Emerging applications of the tumor necrosis factor family of ligands and receptors in cancer therapy. J Clin Oncol 21: 3526-3534, 2003.
18. Chew LJ, Pan H, Yu J, et al: A novel secreted splice variant of vascular endothelial cell growth inhibitor. FASEB J 16: 742-744, 2002.
19. Yao JJ, Zhang M, Miao XH, et al: Isoform of vascular endothelial cell growth inhibitor (VEGI72-251) increases interleukin-2 production by activation of T lymphocytes. Acta Biochim Biophys Sin (Shanghai) 38: 249-253, 2006.
20. Jin T, Kim S, Guo F, Howard A and Zhang YZ: Purification and crystallization of recombinant human TNF-like ligand TL1A. Cytokine 40: 115-122, 2007.
21. Park SS, Lillehoj HS, Hong YH and Lee SH: Functional characterization of tumor necrosis factor superfamily 15 (TNFSF15) induced by lipopolysaccharides and Eimeria infection. Dev Comp Immunol 31: 934-944, 2007.
22. Xiao Q, Hsu CY, Chen H, Ma X, Xu J and Lee JM: Characterization of cis-regulatory elements of the vascular endothelial growth inhibitor gene promoter. Biochem J 388: 913-920, 2005.
23. Kim S and Zhang L: Identification of naturally secreted soluble form of TL1A, a TNF-like cytokine. J Immunol Methods 298: 1-8, 2005.
24. Migone TS, Zhang J, Luo X, et al: TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator. Immunity 16: 479-492, 2002.
25. Bamias G, Mishina M, Nyce M, et al: Role of TL1A and its receptor DR3 in two models of chronic murine ileitis. Proc Natl Acad Sci USA 103: 8441-8446, 2006.
26. Cassatella MA, Pereira-da-Silva G, Tinazzi I, et al: Soluble TNF-like cytokine (TL1A) production by immune complexes stimulated monocytes in rheumatoid arthritis. J Immunol 178: 7325-7333, 2007.
27. Prehn JL, Thomas LS, Landers CJ, Yu QT, Michelsen KS and Targan SR: The T cell costimulator TL1A is induced by FcgammaR signaling in human monocytes and dendritic cells. J Immunol 178: 4033-4038, 2007.
28. Yang CR, Hsieh SL, Teng CM, Ho FM, Su WL and Lin WW: Soluble decoy receptor 3 induces angiogenesis by neutralization of TL1A, a cytokine belonging to tumor necrosis factor superfamily and exhibiting angiostatic action. Cancer Res 64: 1122-1129, 2004.
29. Conway KP, Price P, Harding KG and Jiang WG: The role of vascular endothelial growth inhibitor in wound healing. Int Wound J 4: 55-64, 2007.
30. Carmeliet P: Mechanisms of angiogenesis and arteriogenesis. Nat Med 6: 389-395, 2000.
31. Cai J, Wei R and Cheng J: Preparation and characterization of a novel chimeric protein VEGI-CTT in Escherichia coli. J Biomed Biotechnol 2008: 564969, 2008.
32. Yue TL, Ni J, Romanic AM, et al: TL1, a novel tumor necrosis factor-like cytokine, induces apoptosis in endothelial cells. Involvement of activation of stress protein kinases (stress-activated protein kinase and p38 mitogen-activated protein kinase) and caspase-3-like protease. J Biol Chem 274: 1479-1486, 1999.
33. Tian F, Grimaldo S, Fujita M, Cutts J, Vujanovic NL and Li LY: The endothelial cell-produced antiangiogenic cytokine vascular endothelial growth inhibitor induces dendritic cell maturation. J Immunol 179: 3742-3751, 2007.
34. Papadakis KA, Prehn JL, Landers C, et al: TL1A synergizes with IL-12 and IL-18 to enhance IFN-gamma production in human T cells and NK cells. J Immunol 172: 7002-7007, 2004.
35. Wang AM, Creasey AA, Ladner MB, et al: Molecular cloning of the complementary DNA for human tumor necrosis factor. Science 228: 149-154, 1985.
36. Shirai T, Yamaguchi H, Ito H, Todd CW and Wallace RB: Cloning and expression in Escherichia coli of the gene for human tumour necrosis factor. Nature 313: 803-806, 1985.
37. Aggarwal BB, Eessalu TE and Hass PE: Characterization of receptors for human tumour necrosis factor and their regulation by gamma-interferon. Nature 318: 665-667, 1985.
38. Browning JL, Ngam-ek A, Lawton P, et al: Lymphotoxin beta, a novel member of the TNF family that forms a heteromeric complex with lymphotoxin on the cell surface. Cell 72: 847-856, 1993.
39. Goodwin RG, Alderson MR, Smith CA, et al: Molecular and biological characterization of a ligand for CD27 defines a new family of cytokines with homology to tumor necrosis factor. Cell 73: 447-456, 1993.
40. Stein H, Gerdes J, Schwab U, et al: Identification of Hodgkin and Sternberg-reed cells as a unique cell type derived from a newly-detected small-cell population. Int J Cancer 30: 445-459, 1982.
41. Durkop H, Latza U, Hummel M, Eitelbach F, Seed B and Stein H: Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease. Cell 68: 421-427, 1992.
42. Gauchat JF, Aubry JP, Mazzei G, et al: Human CD40-ligand: molecular cloning, cellular distribution and regulation of expression by factors controlling IgE production. FEBS Lett 315: 259-266, 1993.
43. Takahashi T, Tanaka M, Brannan CI, et al: Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell 76: 969-976, 1994.
44. Takahashi T, Tanaka M, Inazawa J, Abe T, Suda T and Nagata S: Human Fas ligand: gene structure, chromosomal location and species specificity. Int Immunol 6: 1567-1574, 1994.
45. Alderson MR, Smith CA, Tough TW, et al: Molecular and biological characterization of human 4-1BB and its ligand. Eur J Immunol 24: 2219-2227, 1994.
46. Miura S, Ohtani K, Numata N, et al: Molecular cloning and characterization of a novel glycoprotein, gp34, that is specifically induced by the human T-cell leukemia virus type I transactivator p40tax. Mol Cell Biol 11: 1313-1325, 1991.
47. Wiley SR, Schooley K, Smolak PJ, et al: Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3: 673-682, 1995.
48. Lacey DL, Timms E, Tan HL, et al: Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93: 165-176, 1998.
49. Hahne M, Kataoka T, Schroter M, et al: APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth. J Exp Med 188: 1185-1190, 1998.
50. Chicheportiche Y, Bourdon PR, Xu H, et al: TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis. J Biol Chem 272: 32401-32410, 1997.
51. Pradet-Balade B, Medema JP, Lopez-Fraga M, et al: An endogenous hybrid mRNA encodes TWE-PRIL, a functional cell surface TWEAK-APRIL fusion protein. EMBO J 21: 5711-5720, 2002.
52. Moore PA, Belvedere O, Orr A, et al: BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science 285: 260-263, 1999.
53. Takashiba S, Van Dyke TE, Shapira L and Amar S: Lipopolysaccharide-inducible and salicylate-sensitive nuclear factor(s) on human tumor necrosis factor alpha promoter. Infect Immun 63: 1529-1534, 1995.
54. Kwon B, Yu KY, Ni J, et al: Identification of a novel activation-inducible protein of the tumor necrosis factor receptor superfamily and its ligand. J Biol Chem 274: 6056-6061, 1999.
55. Nocentini G, Giunchi L, Ronchetti S, et al: A new member of the tumor necrosis factor/nerve growth factor receptor family inhibits T cell receptor-induced apoptosis. Proc Natl Acad Sci USA 94: 6216-6221, 1997.
56. Mauri DN, Ebner R, Montgomery RI, et al: LIGHT, a new member of the TNF superfamily, and lymphotoxin alpha are ligands for herpesvirus entry mediator. Immunity 8: 21-30, 1998.
57. Harrop JA, McDonnell PC, Brigham-Burke M, et al: Herpesvirus entry mediator ligand (HVEM-L), a novel ligand for HVEM/TR2, stimulates proliferation of T cells and inhibits HT29 cell growth. J Biol Chem 273: 27548-27556, 1998.
58. Agarwal N, Swaroop A, Zheng K, et al: Expression and chromosomal localization of cDNA clones from an enriched human retinal pigment epithelial (RPE) cell line library: identification of two RPE-specific genes. Cytogenet Cell Genet 69: 71-74, 1995.